Obseva Logo highresolution.jpg
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
November 22, 2022 07:00 ET | ObsEva SA
Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 millionThe sale proceeds are expected to enable ObsEva to...
Obseva Logo highresolution.jpg
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
November 22, 2022 01:00 ET | ObsEva SA
Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 millionThe sale proceeds are expected to enable ObsEva to...
Obseva Logo highresolution.jpg
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings
October 26, 2022 17:00 ET | ObsEva SA
Transition of linzagolix program to Kissei Pharmaceutical Co., Ltd. substantially complete with approximately $16.0 million savings expected from assignment of program contracts, including $3.7...
Obseva Logo highresolution.jpg
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
October 13, 2022 07:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – October 13, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel...
Obseva Logo highresolution.jpg
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
October 13, 2022 01:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – October 13, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel...
Obseva Logo highresolution.jpg
ObsEva Announces Progress on Restructuring Initiatives
September 13, 2022 07:00 ET | ObsEva SA
$7.6 million annual savings expected via reduction-in-force currently underway$6.2 million savings expected from assignment of legacy linzagolix program contracts to Kissei Pharmaceutical Co., Ltd.,...
Obseva Logo highresolution.jpg
ObsEva Announces Progress on Restructuring Initiatives
September 13, 2022 01:00 ET | ObsEva SA
$7.6 million annual savings expected via reduction-in-force currently underway$6.2 million savings expected from assignment of legacy linzagolix program contracts to Kissei Pharmaceutical Co., Ltd.,...
Obseva Logo highresolution.jpg
ObsEva Receives Nasdaq Non-Compliance Notice
August 22, 2022 01:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   Geneva, Switzerland and Boston, MA – August 22, 2022 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company...
Obseva Logo highresolution.jpg
ObsEva Files Second Quarter 2022 Financial Statements
August 17, 2022 16:01 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA – August 17, 2022 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company...
Obseva Logo highresolution.jpg
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
August 01, 2022 07:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – August 1, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel...